Usefulness of autologous serum for ocular surface lesions with uncertain progression. A clinical and imaging evaluation
DOI:
https://doi.org/10.24265/horizmed.2021.v21n3.09Keywords:
Serum, Intercellular signaling peptides and proteins, Platelet-rich plasma, Eye injuriesAbstract
Objective: To determine the effectiveness of autologous serum rich in growth factors to repair ocular surface lesions which have uncertain progression with conventional treatment. Materials and methods: AForty-six (46) eyes with ocular surface disorders such as exposure keratopathy, keratopathy caused by dry eye syndrome, neurotrophic keratopathy and blunt eye injury were treated. The affected areas were the conjunctiva, cornea (epithelium, stroma) and sclera. Anatomical and functional evaluations were performed between
March and December 2020 using Schirmer’s test, fluorescein eye stain and optical coherence tomography (OCT). Results: The symptoms improved in the following order: eye pain, foreign body sensation, blepharospasm, hyperemia and epiphora. Additionally, the lesions progressed favorably as follows: first, those of the conjunctiva and corneal epithelium; then, those of the corneal stroma; and, finally, those of the sclera. An average of 15 days was required for immediate ocular surface recovery and 21 days for late recovery. The lesions with total scleral thinning healed in about two months. Conclusions: The findings related to pain threshold, recovery time, scar tissue remodeling of the affected tissue and visual acuity improvement are promising and important. Using autologous serum rich in growth factors may be a therapeutic alternative for those lesions that are difficult to resolve with conventional treatment.
Downloads
References
López-García JS, García-Lozano I, Rivas L, Martínez-Garchitorena J. Use of autologous serum in ophthalmic practice. Arch Soc Esp Oftalmol. 2007; 82(1): 9-20.
Geerling G, MacLennan S, Hartwig D. Autologous serum eye drops for ocular surface disorders. Br J Ophthalmol. 2004; 88(11): 1467-74.
León-Hernández FA, Taboada Esteve JF. Traumatismos Oculares graves en España: factores epidemiológicos, estudio de las lesiones y medidas de prevención. Barcelona; 1994. p. 12-27.
Ministerio de Salud. Guía Clínica: Trauma ocular grave [Internet]. MINSAL: Santiago; 2009. Disponible en: http://www.bibliotecaminsal.cl/wp/wp-content/uploads/2016/04/Trauma-Ocular-Grave.pdf
Díaz-Mendoza JJ, Chirinos-Saldaña MP, Uribe-Villarreal J, Hilario-Vargas J, Adrianzén RE. Características epidemiológicas de los traumatismos oculares en un instituto oftalmológico de referencia regional, Trujillo Perú, 2016-2017. Acta Med Perú. 2019; 36(4): 281-6.
Sánchez Tocino H, Galindo Ferreiro A, Iglesias Cortiñas D, Galindo Alonso J, Fernández Muñoz M. Estudio epidemiológico de las urgencias oftalmológicas en un hospital general. Arch Soc Esp Oftalmol. 2004; 79(9): 425-32.
Ameloot F. Activité et épidémiologie d’une unité d’urgence ophtalmologique récemment crééé au Centre Hospitalier Universitaire de Nancy. Université de Lorraine; 2012.
Edwards RS. Ophthalmic emergencies in a district general hospital casualty department. Br J Ophthalmol. 1987; 71(12): 938-42.
Nash EA, Margo CE. Patterns of emergency department visits for disorders of the eye and ocular adnexa. Arch Ophthalmol. 1998; 116(9): 1222-6.
Kanski JJ, Ofatlmología Clínica. 5ta ed. Barcelona: Elsevier; 2008. p. 689-91.
Ministerio de Trabajo y Promoción del Empleo. Notificaciones de accidentes de trabajo, incidentes peligrosos y enfermedades ocupacionales – Edición junio 2020 [Internet]. MTPE: Lima; 2020. Disponible en: https://www.gob.pe/institucion/mtpe/informes-publicaciones/1090070-boletin-estadistico-mensual-notificaciones-de-accidentes-de-trabajo-incidentes-peligrosos-y-enfermedades-ocupacionales-edicion-junio-2020
Instituto Nacional de Oftalmología. Departamento Estadística del Instituto Nacional de Oftalmología [Internet]. INO: Lima. Disponible en: https://www.ino.gob.pe/estadistica/
Ramos T, Scott D, Ahmad S. An update on ocular surface epithelial stem cells: cornea and conjunctiva. Stem Cells Int. 2015.
Harguindey S, Reshkin SJ, Orive G, Arranz JL, Anitua E. Growth and trophic factors, pH and the Na+/H+ exchanger in Alzheimer's disease, other neurodegenerative diseases and cancer: new therapeutic possibilities and potential dangers. Curr Alzheimer Res. 2007; 4(1): 53-65.
Grayson M. Enfermedades de la có rnea. Bogotá : Médica Panamericana; 1985.
Rezende Ribeiro MVM, Falcao de Melo V, Calado Barbosa MEF, de Franca Tozzi MU, Baracho Ramos MS, Soares Gaia NMSR, et al. The use of platelet rich-plasma in Ophthalmology: a literature review. Rev Bras Oftalmol. 2017; 76(6): 319-24.
Imanishi J, Kamiyama K, Iguchi I, Kita M, Sotozono C, Kinoshita S. Growth factors: importance in wound healing and maintenance of transparency of the cornea. Prog Retin Eye Res. 2000; 19(1): 113-29.
Urzua C, Vasquez DH, Huidobro A, Hernandez H, Alfaro J. Randomized double-blind clinical trial of autologous serum versus artificial tears in dry eye syndrome. Curr Eye Res. 2012; 37(8): 684-8.
Borzini P, Mazzucco I. Platelet-rich plasma (PRP) and platelet derivatives for topical therapy. What is true from the biological view point?. ISBT Science Series. 2007; 2(1): 272-81.
Montón-Echevarría J, Pérez Redondo S, Gómez Bajo GJ. Experiencia clínica en el empleo de factores de crecimiento autólogos obtenidos de plasma rico en plaquetas. Cir Plást Iberolatinoam. 2007; 33(3): 155-62.
Solans Pérez de Larraya AM, Salgado Miranda AD, Ortega Molina JM, Chaves Samaniego MJ. Plasma enriquecido en plaquetas: una alternativa como tratamiento de la patología oftalmológica. Annals d'oftalmologia. 2015.
García Jiménez V, Veiga Villaverde B, Baamonde Arbaiza B, Carpintero IC, Celemín Viñuela ML, Simó Martínez RM. Elaboración, utilización y evaluación de un colirio con suero autólogo en las lesiones corneales. Farmacia hospitalaria. 2003; 27(1): 21-5.
Márquez De Aracena Del Cid R, Montero-Espinoza I, Pereira Gutiérrez G, Martín Leal F. Subconjunctival and topic treatment of plasma platelet concentrate in limbal transplantion. Mapfre Medicina. 2006; 17(4): 280-5.
Published
How to Cite
Issue
Section
License
Copyright (c) 2021 Horizonte Médico (Lima)
This work is licensed under a Creative Commons Attribution 4.0 International License.
Horizonte Médico (Lima) (Horiz. Med.) journal’s research outputs are published free of charge and are freely available to download under the open access model, aimed at disseminating works and experiences developed in biomedical and public health areas, both nationally and internationally, and promoting research in the different fields of human medicine. All manuscripts accepted and published in the journal are distributed free of charge under the terms of a Creative Commons license – Attribution 4.0 International (CC BY 4.0).
